GRAL

#1697
GRAIL, Inc. - Common Stock
72.7 0 USD
+0.03%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
72.70
72.70
Year Range
41.50
102.52
Daily Change
+3.46%
Monthly Change
+5.71%
6 month change
-26.57%
Year Change
-26.57%
Previous Close
70.2 7
Open
72.7 0
Low
72.7 0
High
72.7 0
Volume
85
Open full chart

Financials

Overview Statement Statistics Documents

2026

Current report, Q2 FY2026
GRAIL, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
GRAIL, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
GRAIL, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
GRAIL, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
GRAIL, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
GRAIL, Inc. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
GRAIL, Inc. annual report, FY2025
10-K
Current report, Q4 FY2025
GRAIL, Inc. current report, Q4 FY2025
8-K
Current report, Q4 FY2025
GRAIL, Inc. current report, Q4 FY2025
8-K
Current report, Q4 FY2025
GRAIL, Inc. current report, Q4 FY2025
8-K

GRAIL, Inc. current report, Q2 FY2024

Full document

Business Context and Reporting Period

Company: GRAIL, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 24, 2024
Event: Completion of the Spin-Off from Illumina, Inc. and announcement of material asset impairments.

Key Financial Metrics and Material Changes

This filing reports significant non-cash impairment charges resulting from the application of pushdown accounting following the separation from Illumina. The Company estimates the following charges for the second quarter of 2024:

  • Goodwill Impairment: Estimated at $888.9 million, representing the full remaining carrying value of goodwill as of March 31, 2024.
  • IPR&D Intangible Assets Impairment: Estimated at approximately $420.0 million. As of March 31, 2024, the carrying value of these assets was $560.0 million.
  • Total Estimated Impairment: Approximately $1.309 billion ($888.9 million + $420.0 million).

Cash Flow Impact: The Company explicitly states it does not expect any material future cash expenditures related to these impairments.

Guidance, Outlook, and Management Commentary

Impairment Testing Status: The Company has not yet completed its interim impairment test for goodwill and indefinite-lived intangible assets but expects to recognize the estimated charges in the second quarter of 2024.
Future Risks: The Company will continue to review and monitor for any further impairment indicators that could result in additional charges in the second quarter.
Reporting Timeline: Additional details regarding these charges will be provided in the Form 10-Q filing for the quarter ended June 30, 2024.

Investor Verification Checklist

  • Verify the final impairment amounts in the upcoming Form 10-Q for the quarter ended June 30, 2024.
  • Confirm the impact of the $1.309 billion estimated charge on the Company's net income and retained earnings.
  • Review the updated balance sheet to ensure the removal of the impaired goodwill and IPR&D assets.
  • Monitor for any further impairment indicators mentioned by management that could increase the total charge beyond current estimates.